LTF and prostate carcinoma: AR signaling plays a central role in prostate cancer development and progression, and AR-targeted therapies such as enzalutamide (ENZ) have become standard treatments.41 ENZ inhibits the AR signaling pathway, which regulates key processes including lipid metabolism, oxidative stress, and iron homeostasis, all of which influence ferroptosis regulation.32,42 While our findings highlight LTF as a central player, the broader effects of ENZ on ferroptosis likely arise from its modulation of AR-dependent pathways.